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Abstract Tyrosine-protein phosphatase nonreceptor type 12
(PTPN12) has been proposed to predict prognosis of various
human cancers. However, the clinicopathologic and prognos-
tic significance of PTPN12 expression in NPC has not yet
been elucidated. The objective of this study was to investigate
the clinicopathological and prognostic implication of PTPN12
in nasopharyngeal carcinoma (NPC) patients. Protein expres-
sion levels of PTPN12 were explored by semiquantitative im-
munohistochemical staining on archival formalin-fixed,
paraffin-embedded pathological specimens consisting of 203
NPCs, and 40 normal nasopharyngealmucosa tissues. Receiv-
er operating characteristic (ROC) curve analysis was
employed to determine the cutoff score of PTPN12 expression
in NPCs. The PTPN12 immunohistochemical staining results
were then correlated with various clinicopathological features
and patients’ prognosis using various statistical models. Our
results showed that decreased expression of PTPN12 was
more frequently observed in NPC tissues compared with the
normal nasopharyngeal mucosa. Further correlation analyses
indicated that the decreased expression of PTPN12 was sig-
nificantly associated with tumor T classification, N classifica-
tion, distant metastasis, and clinical stage in NPCs (P<0.05).
Univariate analysis showed a significant association between
the decreased expression of PTPN12 and adverse overall sur-
vival and disease-free survival (P<0.05). More importantly,
multivariate analysis identified the PTPN12 expression in
NPC as an independent prognostic factor. The decrease ex-
pression of PTPN12 might be important in conferring a more
aggressive behavior in NPC. Thus, PTPN12 expression may
be used as a novel independent prognostic biomarker for pa-
tients with NPC.
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Introduction
Nasopharyngeal carcinoma (NPC) is the most common cancer
originating from the nasopharynx, which is prevalent in south-
east Asia, especially in southern China, where it constitutes a
significant health burden [1]. Most of NPC cells are undiffer-
entiated or poorly differentiated with the following character-
istics: fast growth, invading adjacent regions, and metastasiz-
ing to regional lymph nodes and/or distant organs. With the
advancement of the diagnostic and treatment techniques, the
local-regional control rate for NPC has improved significantly
in the past few decades, but the incidence of metastasis has not
decreased greatly. If metastasis occurs, the outcome is very
poor [2]. Epstein–Barr virus (EBV) infection is believed to
be the major factor of NPC [3]. This infection initiates a mul-
tistep process with morphological progression involving mul-
tiple genetic and epigenetic events [1, 4]. Identification of
molecular and biological changes that occur during
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carcinogenesis and/or progression could facilitate investiga-
tion of the signal pathway of NPC and generate new prognos-
tic markers to more accurately predict patients’ clinical out-
come and contribute to individualize treatments for NPC pa-
tients. Therefore, it is urgently needed to develop new bio-
markers for clinical diagnosis/prognosis and find novel effec-
tive therapies for NPC.
Tyrosine-protein phosphatase nonreceptor type 12
(PTPN12) is one of ubiquitously expressed cytosolic protein
tyrosine phosphatases (PTPs) family with an amino (N)-ter-
minal PTP domain and a carboxyl (C)-terminal region in-
volved in protein–protein interactions [5]. PTPs play an im-
portant role in signal transduction and regulation in cellular
physiology and cancer [6, 7]. These PTPs can also serve as
antagonists to tyrosine kinase (TK) signaling, thereby playing
a prominent role in tumor suppression [8, 9]. PTPN12 is a key
regulator of integrin-mediated adhesion and migration of en-
dothelial cells by dephosphorylating the cytoskeleton regula-
tors Cas, paxillin, and Pyk2, such an activity likely explains
the critical role of PTPN12 in vascular development and tu-
mor formation [10]. Also, PTPN12 is required for secondary
T cell responses, energy prevention, and autoimmunity induc-
tion [11]. Recent studies showed that PTPN12 inhibits
growth, proliferation, tumorigenicity, and metastatic potential
in triple-negative breast cancer [12] and colon cancer [13], and
also found to be a prognostic biomarker for esophageal squa-
mous cell carcinoma [14]. However, there are no relevant
reports on the prognostic value of PTPN12 in NPCs. In this
study, we investigated the expression status of PTPN12 pro-




The study was approved by the Institute Research Medical
Ethics Committee of Sun Yat-sen University. No informed
consent (written or verbal) was obtained for use of retrospec-
tive tissue samples from the patients within this study, most of
whomwere deceased, since this was not deemed necessary by
the ethics committee, who waived the need for consent. All
samples were anonymized.
Patients and tissue specimens
In this study, 203 specimens of NPC were collected in Sun
Yat-sen University Cancer Center and in Guangdong Provin-
cial People’s Hospital, Guangzhou, China, between January
1991 and August 2000. The selection of cases was based on
the following criteria: pathologically confirmed as
nonkeratinizing carcinoma of nasopharynx (World Health
Organization types of II or III) with available biopsy speci-
mens for tissue microarray (TMA) construction; no previous
malignant disease or a second primary tumor; without radio-
therapy, chemotherapy history before biopsy; Karnofsky ≥70;
received radiotherapy (RT), induction chemotherapy/
radiotherapy (IC/RT), or induction chemotherapy/
chemoradiotherapy (IC/CRT) regimen; and follow-up regular-
ly. Patients with unavailable biopsy tissues for constructing
TMAwere excluded from our study to provide adequate sam-
ples for pathological diagnosis. We chose 203 primary NPCs
from the Department of Pathology of our institutes, and 40
samples of normal nasopharyngeal mucosa were used for con-
trols. The routine staging workup was composed of a detailed
p h y s i c a l e x am i n a t i o n , i n c l u d i n g f i b e r o p t i c
nasopharyngoscopy, magnetic resonance imaging (MRI) of
the entire neck, chest X-ray, abdominal ultrasonography, a
complete blood count, and a biochemical profile. The clinical
stage was defined on the basis of the International Union
Against Cancer (UICC) and the American Joint Committee
on Cancer (AJCC) [15]. The Institute Research Medical
Ethics Committee of Sun Yat-Sen University Cancer Center
granted approval for this study.
Follow-up
The response of RT or CRTwas assessed clinically for prima-
ry lesion based on fiber optic nasopharyngoscopy and MRI
1month after treatment. In our study, the patients were follow-
ed every 3 months for the first year and then every 6 months
for the next 2 years and finally annually, thereafter. The diag-
no s t i c e x am in a t i o n s c on s i s t e d o f f i b e r op t i c
nasopharyngoscopy, MRI, CT, chest X-ray, abdominal ultra-
sonography, and bone scan when necessary to detect recur-
rence and/or metastasis. The total follow-up period was de-
fined as the time from diagnosis to the date of death or the last
date censored if patients were still alive.
Tissue microarray
TMA was constructed in accordance with a previously de-
scribed method [16]. In brief, the paraffin-embedded tissue
blocks and the corresponding histological H&E-stained slides
were overlaid for tissue TMA sampling. Duplicate of 0.6 mm
diameter cylinders were punched from representative tumor
areas of individual donor tissue block, and re-embedded into a
recipient paraffin block at a defined position, using a tissue
arraying instrument (Beecher Instruments, Silver Spring, MD,
USA).
Immunohistochemistry
Formalin-fixed, paraffin-embedded NPC samples were cut
into 4-μm thick sequential sections and processed for
5202 Tumor Biol. (2015) 36:5201–5208
immunohistochemistry (IHC) according to the previously de-
scribed protocol [17]. The TMA slides were deparaffinized in
xylene, rehydrated through graded alcohol, immersed in 3 %
hydrogen peroxide for 10 min to block endogenous peroxi-
dase activity and antigen retrieved by pressure cooking for
3 min in citrate buffer (pH=6). For blocking nonspecific bind-
ing, the slides were preincubated with 10 % normal goat se-
rum at room temperature for 20 min. Subsequently, the slides
were incubated with rabbit polyclonal antibody anti-PTPN12
(1:300 dilution), overnight at 4 °C in a moist chamber. The
slides were sequentially incubated with a secondary antibody
(Envision, Dako, Denmark) for 30 min in the incubator at
37 °C and stained with 3,3-diaminobenzidine (DAB). Finally,
the sections were counterstained with Mayer’s hematoxylin,
dehydrated, and mounted. A negative control was obtained by
replacing the primary antibody with a normal rabbit IgG.
IHC evaluation
According to our previous study [17], protein expression
levels of PTPN12 were evaluated bymicroscopic examination
of stained TMA slides. The presence of cytoplasmic brown
granules was considered to be positive for PTPN12 expres-
sion. In brief, the expression pattern was assessed as follows:
each TMA spot was assigned an intensity score from 0 to 3
(I0; I1; I2; I3, 0, negative; 1, weak; 2, moderate; and 3, strong).
Then, cytoplasmic PTPN12 was evaluated according to the
percentage of positively stained cells in 5 % increments from
0 to 100 %. The final H score (range, 0–300) was determined
by adding the sum of the scores obtained for each intensity
and the proportion of the area stained (H score=I1*P1+
I2*P2+I3*P3). PTPN12 expression was assessed by two in-
dependent pathologists (Zhang and Luo) who were blinded to
the clinicopathological data. All lab methods were used for
both tumor and nontumor specimens.
Selection of cutoff score
The plot of sensitivity versus 1-specificity across varying cut-
offs generates a curve in the unit square called an receiver
operating characteristic (ROC) curve, the optimal cutoff value
can be determined using ROC curve analysis by the point (0.0,
1.0) or (1.0, 0.0) [18, 19], at the PTPN12 score, the sensitivity
and specificity for each outcome under study was plotted, and
generating various ROC curves. The score was selected as the
cutoff value which was closest to the point with both maxi-
mum sensitivity and specificity. The score below or equal to
the cutoff value was served as decreased expression of
PTPN12, on the contrary, above the cutoff value was seen as
normal expression. To use ROC curve analysis, the clinico-
pathological characteristics were involved: T classification
(T1–T2 versus T3–T4), N classification (N0–N1 versus N2–
N3), distant metastasis (M0 versus M1), clinical stage (I–II
versus III–IV), survival status (death due to NPC versus cen-
sored), and cancer recurrence (yes versus no).
Statistical analysis
Statistical analyses were performed using SPSS software, ver-
sion 16.0 (SPSS, Chicago, USA). The correlation between
PTPN12 expression and clinicopathological features of NPC
patients was assessed by Chi-square test. Univariate analysis
of overall survival (OS; the proportion of cancer patients who
survived for a specified time interval after diagnosis) and
disease-free-survival (DFS) data were performed using the
Kaplan–Meier method. The Cox proportional hazards regres-
sion model was used to identify the independent prognostic
factors. A two-tailed P value of less than 0.05 was considered
as statistically significant in all cases.
Results
Patients’ characteristics
The clinicopathological characteristics of NPC patients were
detailed in Table 1. This NPC cohort consisted of 148
(72.9 %) men and 55 (27.1 %) women with median age of
47 years. Average follow-up period was 72.9 months (median,
73.0 months; range, 3.0 to 233.0 months); 138 patients
(68.0 %) were diagnosed at late stages (III and IV), and the
other 65 patients (32.0 %) were at early stages (I and II).
Selection of the cutoff score for PTPN12 expression
Since the IHC scores were evaluated semiquantitatively, in
our study, we utilized ROC curve analysis to avoid the use
of predetermined and often arbitrarily set cutoff values. ROC
curves are commonly used in clinical oncology to evaluate
and compare the sensitivity and specificity of diagnostic tests.
Moreover, they allow one to identify the threshold value
above which a test result should be considered positive for
some outcome (Fig. 1). In immunohistochemical evaluation,
the score with the shortest distance from the curve to the point
with both maximum sensitivity and specificity, i.e., the point
(1.0, 0.0) or (0.0, 1.0), was selected as the cutoff score leading
to the greatest number of tumors correctly classified as having
or not having the clinical outcome [19, 20].
To select an optimal PTPN12 cutoff score for further anal-
ysis, the ROC curves for each clinicopathological feature
(Fig. 2) show the arrow on the curve closest to the point
(1.0, 0.0), which maximizes both the sensitivity and specific-
ity for the outcome [17, 19], cancers with score above the
obtained cutoff value were considered as normally expressed
PTPN12, which led to the greatest number of cancers classi-
fied as having or not having the clinical outcome. As it was
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shown in Fig. 2, the N classification had the closest to the
point (1.0, 0.0). Based on this outcome, we selected a PTPN12
expression score of 225 defined by the N classification as the
optimal cutoff value for survival analysis. According to the
ROC curve analysis, decreased expression of PTPN12 could
be examined in 125/203 (61.6 %) of NPCs and in 14/40
(35.0 %) of normal nasopharyngeal mucosa, respectively. De-
creased expression of PTPN12 in normal nasopharyngeal tis-
sues is significantly lower than that in NPC (P<0.001).
The relationship between PTPN12 expression
and the clinicopathological features of NPC patients
The rates of normal and decreased expression of PTPN12 in
NPCs about several clinicopathological features were detailed
in Table 1. The results showed that decreased expression of
PTPN12 was significantly correlated with cancer T classifica-
tion, N classification, distant metastasis, and clinical stage
(P<0.05; Table 1), and there was no significant association
between PTPN12 expression and other clinicopathological
features, such as patient sex, age, and cancer histological clas-
sification (P>0.05; Table 1).
The relationship between PTPN12 expression and NPC
patients’ survival
In this study, we firstly tested well established prognostic fac-
tors of patient survival. Univariate analysis evaluated a signif-
icant impact of well-known clinicopathological prognostic
factors (i.e., T classification, N classification, distant metasta-
sis, clinical stage) on NPC patients’ survival rates (P<0.05;
Table 2). Univariate analysis demonstrated that decreased ex-
pression of PTPN12 was correlated significantly with adverse
disease-free survival (P=0.001, Fig. 3a, Kaplan–Meier meth-
od) and overall survival (P<0.0001; Table 2; Fig. 3b, Kaplan–
Meier method). PTPN12 expression and other clinicopatho-
logical features were all included in multivariate analysis
(Table 2). Our results showed that the decreased expression
of PTPN12 was an independent prognostic factor for overall
survival (Cox regression model; hazard ratio, 0.465 (95 % CI,
0.263–0.822), P=0.008; Table 2).
Further analysis showed that 69 of 125 patients with de-
creased expression of PTPN12 and 57 of 78 patients with
normal expression of PTPN12 survived more than 5 years.
The 5-year overall survival rate (78%) of patients with normal
PTPN12 expression was significantly higher than that of pa-
tients with decreased PTPN12 expression (55 %), suggesting
the patients with normal expression of PTPN12 had better
prognosis than those with decreased expression of PTPN12.
Discussion
NPC is characterized by poorly or undifferentiated carcinoma.
It differs from nonnasopharyngeal head and neck squamous
cell carcinomas in several ways, including its association with
the Epstein–Barr virus (EBV) and strong sensitivity for radio-
therapy and chemotherapy. High death rate is mainly due to
tumor metastasis despite the new treatment that combines ra-
diotherapy with chemotherapy [21]. Clinical staging system
for NPC is now being used widely throughout the world to
predict the patients’ prognosis. Patients with the same clinical
staging might have different prognosis after receiving a simi-
lar treatment, therefore, it is necessary to make new objective
strategies that can effectively distinguish between patients
with better or worse prognosis in the same stage. Although,
previous studies demonstrated many aberrantly expressed
genes in NPC [22, 23]. However, novel molecular markers
that can identify tumor recurrence risk remain to be urgently
needed.
Table 1 Correlation between the expression of PTPN12 and










Female 55 38 (69.1 %) 17 (30.9 %) 0.180
Male 148 87 (58.8 %) 61 (41.2 %)
Age at diagnosis (years)
≤45 86 55 (64.0 %) 31 (36.0 %) 0.551
>45 117 70 (59.8 %) 47 (40.2 %)
Histological classification (WHO)
Type II 53 31 (58.5 %) 22 (41.5 %) 0.591
Type III 150 94 (62.7 %) 56 (37.3 %)
T classification
1 26 13 (50.0 %) 13 (50.0 %) 0.010
2 67 40 (59.7 %) 27 (40.3 %)
3 65 35 (53.8 %) 30 (46.2 %)
4 45 37 (82.2 %) 8 (17.8 %)
N classification
0 40 18 (45.0 %) 22 (55.0 %) 0.000
1 94 49 (52.1 %) 45 (47.9 %)
2 48 41 (85.4 %) 7 (14.6 %)
3 21 17 (81.0 %) 4 (19.0 %)
Distant metastasis
0 152 87 (57.2 %) 65 (42.8 %) 0.028
1 51 38 (74.5 %) 13 (25.5 %)
Clinical stage
I 10 3 (30.0 %) 7 (70.0 %) 0.005
II 55 28 (50.9 %) 27 (49.1 %)
III 78 48 (61.5 %) 30 (38.5 %)
IV 60 46 (76.7 %) 14 (23.3 %)
a Chi-square test; WHO, World Health Organization
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Fig. 2 ROC curve analysis was
conducted to determine the cutoff
score for decreased PTPN12
expression. The sensitivity and
specificity for each outcome were
plotted: T classification (a), N
classification (b), M classification
(c), stage (d), survival status (e),
and recurrence (f)
Fig. 1 The expression pattern of PTPN12 protein in NPC and
noncancerous nasopharyngeal tissues. a Negative expression of
PTPN12 was shown in a NPC case (×100). b The micrograph with the
H score <50 of PTPN12 IHC was shown in a NPC case (×100). cANPC
case demonstrated the expression of PTPN12 with the H score of 50~200
(×100). d A NPC case demonstrated the expression of PTPN12 with the
H score of 225 (×100). e A NPC case demonstrated the expression of
PTPN12 with the H score over 250 (×100). f NPC tissue demonstrated
decreased expression of PTPN12 protein with the control of normal
expression of PTPN12 in normal nasopharyngeal mucosal tissue
(×100). g Normal expression of PTPN12 protein was shown in normal
nasopharyngeal mucosal tissue (×100). h The negative control staining.
The lower panels indicated the higher magnification (×200) from the
upper panels
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PTPN12 is one of the PTPs families regulating the equilib-
rium of tyrosine phosphorylation and plays a prominent role
in tumor suppression. The PTPN12 protein is thought to act as
an important regulator in controlling cell adhesion, motility,
and metastasis by interacting with and inhibiting multiple on-
cogenic tyrosine kinases [24]. Recently, it was uncovered that
PTPN12 is a tumor suppressor in human breast cancer and
lung cancer, seemingly as a result of its capacity to control
receptor PTK signaling [12]. In recent years, decreased ex-
pression of PTPN12 has been shown to be correlated with
the development and progression of different human cancers,
including breast cancer, hepatocellular carcinoma, and esoph-
ageal squamous cell carcinoma [12, 14, 17, 25]. Silencing of
PTPN12 has been shown to enhance migration in ovarian
cancer and colon cancer cells [13, 26]. However, expression
of the PTPN12 protein in NPC and its prognostic significance
in NPC are still unclear. In this study, we examined the
PTPN12 protein expression in 203 NPC tissues and 40 normal
nasopharyngeal mucosal tissues. Our results revealed that de-
creased expression of PTPN12 in normal nasopharyngeal tis-
sues is significantly lower than that in NPC. Although the
expression levels of PTPN12 in the NPC and normal naso-
pharyngeal tissues is significantly different, 14 of 40 normal
nasopharyngeal tissues presented the decreased expression of
PTPN12. The majority of NPCs had a lower expression of
PTPN12 than that in nonneoplastic nasopharyngeal tissues
in our study. These studies suggested that PTPN12 may be a
tumor suppressor in human cancers. Further correlation anal-
yses showed that the decreased PTPN12 expression was
closely correlated with tumor stage, suggesting that PTPN12
might inhibit the differentiation and proliferation of NPC.
Moreover, analysis of the association of PTPN12 expression
with clinicopathological characteristics implied that the de-
creased expression of PTPN12 was related to lymph nodes
Table 2 Univariate and
multivariate analyses of different
prognostic variables in 203
patients with nasopharyngeal
carcinoma for overall survival
CI confidence interval, WHO
World Health Organization
aCox regression model
Variable All cases Univariate analysisa Multivariate analysisa
Mean survival
(mean±SD)




Female 55 130.70±12.94 0.710 0.891 (0.535–1.482) 0.656
Male 148 157.50±8.14
Age at surgery (years)
≤45 86 121.05±8.20 0.386 0.816 (0.516–1.290) 0.384
>45 117 161.22±9.17
Histological classification (WHO)
Type II 53 179.49±12.27 0.074 1.844 (1.026–3.313) 0.041
Type III 150 120.44±6.29
T classification










0 152 171.75±7.76 0.000 0.862 (0.400–1.856) 0.704
1 51 69.31±6.67
Clinical stage





Decreased 125 110.77±7.00 0.000 0.465 (0.263–0.822) 0.008
Normal 78 189.68±9.29
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metastasis, which was consistent with the evidence provided
by Xunyi et al. [27]. Our findings support the critical role of
PTPN12 as a tumor suppressor in the development and pro-
gression of NPC. Collectively, these data suggest that
PTPN12 functions as a suppressor of malignant transforma-
tion and may be inactivated in human cancers. In addition, as
an independent prognostic factor, decreased expression of
PTPN12 was significantly correlated with the poor prognosis
of NPC patients, as evidenced by univariate and multivariate
Cox regression analysis. These findings were similar to that in
other studies [13, 25, 26]; a strong correlation between the
decreased expression PTPN12 and shortened survival was
found in breast cancer, indicating that inactivated PTPN12
may result in aggressive proliferation of tumors and can be
used as a key biomarker for the assessment of prognosis in
human cancers.
We found that the expression of PTPN12 protein could be
influenced by some factors including missense mutation of
PTPN12 gene [24]. This literature reported that both human
cancers and normal tissues appeared to themissensemutations
of PTPN12 gene, which could produce three mutant variants
of PTPN12 protein consisting of two variants with normal or
high expression and a variant with decreased expression of
PTPN12 in the majority of human cancer samples by immu-
noblotting, and the majority of normal tissues were served as
nonmutant variant with normal or high expression of
PTPN12, and rare tissues were regarded as mutant variant
with decreased expression of PTPN12. However, we specu-
late that PTPN12 may maintain normal level in the NPC with
normal modulation of cell-mediated immunity, once the im-
munity environment changed abnormal, PTPN12 might be
compromised in NPC by deletion, activating silent sequence
variants or loss of expression. Prior reports showed that
PTPN12 acts as a negative regulator of tyrosine phosphoryla-
tion not only of p130cas and FAK as previously reported in
other cells but also of TrkB [28, 29]; promoter CpG island
hypermethylation occurs more frequently in breast cancer
cases and breast cancer cell lines with low PTPN12 expression
[27], indicating that it is a potentially mechanism leading to
PTPN12 downregulation. Nevertheless, the underlying mech-
anism by which PTPN12 affects prognosis remains unclear
and will require further investigation, Therefore, we will deep-
ly study the mechanisms underlying PTPN12 association
gene-mediated progression and metastasis of NPC in future
experiments, by identifying the receptor, adapters, target pro-
teins, and pathways of the abovementioned gene.
In summary, our study showed that the examination of
PTPN12 expression by IHC could serve as an effective tool
in identifying those NPC patients at increased risk of tumor
invasiveness and metastasis, and also elaborate decreased
PTPN12 expression as a novel adverse independent prognos-
tic factor in NPC, which may help us find new therapeutic
target.
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